Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: A cohort study

  • Authors:
    • Yun-Xia Chai
    • Jian-Lei Ji
    • Shu-Juan Li
    • Yan-Wei Cao
    • Xiao-Xia Sun
    • Qing-Hai Wang
    • Tao Huang
    • Zhen Dong
    • Hong-Yang Wang
  • View Affiliations

  • Published online on: January 15, 2020     https://doi.org/10.3892/etm.2020.8451
  • Pages: 2384-2390
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anti-T-lymphocyte globulin (ATG) is frequently used in the induction regimen of renal transplantation, but its dose has not been standardized. In the present study, the efficacy of different ATG-Fresenius (ATG-F) doses was assessed in recipients of renal transplantation. A total of 131 adult recipients of renal transplantation who received ATG-F induction between August 2015 and July 2018 were included. The incidence of biopsy-confirmed acute rejection, graft function, as well as graft and patient survival within 12 months post-transplant, was assessed, and adverse events, including hematologic and infection-associated side effects, were compared between patients receiving a cumulative ATG-F dose of <7 or ≥7 mg/kg. The incidence of biopsy-confirmed acute rejection was similar between patients receiving cumulative doses of <7 and ≥7 mg/kg (7.5 vs. 4.7%, P=0.766). The incidence of infection within 12 months was lower in the ATG-F <7 mg/kg group compared with that in the ≥7 mg/kg group (26.9 vs. 50.0%, P=0.006), but the incidence of pneumonia did not differ between the ATG-F <7 and ≥7 mg/kg groups (10.4 vs. 20.3%, P=0.117). The incidence of urinary infection was higher in the ≥7 mg/kg group than in the <7 mg/kg group (20.4 vs. 7.46%, P=0.033), while the extent and duration of anemia and lymphopenia was similar between groups. There was no difference in graft function, delayed graft function, as well as overall and graft survival between the groups. In conclusion, a moderate reduction in the cumulative ATG-F dose was not associated with an increased risk of acute rejection, while the risk of infection was reduced. Optimization of the ATG-F dose for induction may facilitate the reduction of the risk of infection without compromising the induction efficacy in renal transplant recipients.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Chai, Y., Ji, J., Li, S., Cao, Y., Sun, X., Wang, Q. ... Wang, H. (2020). Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: A cohort study. Experimental and Therapeutic Medicine, 19, 2384-2390. https://doi.org/10.3892/etm.2020.8451
MLA
Chai, Y., Ji, J., Li, S., Cao, Y., Sun, X., Wang, Q., Huang, T., Dong, Z., Wang, H."Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: A cohort study". Experimental and Therapeutic Medicine 19.3 (2020): 2384-2390.
Chicago
Chai, Y., Ji, J., Li, S., Cao, Y., Sun, X., Wang, Q., Huang, T., Dong, Z., Wang, H."Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: A cohort study". Experimental and Therapeutic Medicine 19, no. 3 (2020): 2384-2390. https://doi.org/10.3892/etm.2020.8451